---
layout: default
title: Granisetron
parent: 僅模型預測 (L5)
nav_order: 167
evidence_level: L5
indication_count: 10
---

# Granisetron
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# GRANISETRON: From Antiemetic Use to Manic Bipolar Affective Disorder

## One-Sentence Summary

Granisetron is a 5-HT3 receptor antagonist; the evidence pack does not provide structured data on its original approved indication, and the drug is not currently marketed in Norway.
The TxGNN model predicts it may be effective for **manic bipolar affective disorder**,
but this prediction is supported by **0 clinical trials** and **0 publications** — it is a model-only signal with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack (drug class noted as 5-HT3 receptor antagonist; no approved indication text or license data available) |
| Predicted New Indication | Manic bipolar affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the information present in the evidence pack, granisetron is described as a **5-HT3 receptor antagonist**, a drug class whose established clinical use is antiemetic therapy (e.g., chemotherapy/radiotherapy-induced nausea and vomiting). No structured "original indication" field or Norwegian market license data is present to confirm this formally.

The rationale supplied for the top prediction states that 5-HT3 antagonism could theoretically modulate serotonergic tone, and serotonin has an indirect relationship to mood regulation. However, the same rationale explicitly notes that manic/bipolar pathology is primarily driven by **dopaminergic and GABAergic** dysregulation, not serotonergic 5-HT3 signaling — meaning the mechanistic bridge here is speculative rather than established.

Because this is a pure network-based prediction with no supporting trials or literature, the mechanistic plausibility alone is insufficient to move this candidate beyond an early screening stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Norway Market Information

Granisetron currently holds no market authorizations in Norway (0 licenses on record); the product is not marketed.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests solely on a TxGNN network score (L5) with no clinical trials, no literature, no confirmed MOA, and no market presence in Norway to anchor a mechanistic or regulatory assessment. The drug's own repurposing rationale acknowledges the mechanistic link to bipolar mania is weak and indirect.

**To proceed, the following is needed:**
- TFDA-equivalent label warnings/contraindications (currently a blocking data gap, DG001)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- Original approved indication and licensing status to establish a baseline for comparison
- At minimum, preclinical or observational evidence directly linking 5-HT3 antagonism to mood/manic symptom modulation before this candidate can advance past S0

*Note: All 10 predicted indications in this evidence pack are rated L5/Hold with no supporting trials or literature — this candidate set as a whole is at the earliest possible screening stage.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

